Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Pollard

Showing results (601-610 of 642) with videos related to

Pageof 65
Sort By:
Journal of Neurotrauma|December 31, 2010
Craniotomy: true sham for traumatic brain injury, or a sham of a sham?Jeffrey T Cole, Angela Yarnell, William S Kean, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
International Journal of Cancer|January 3, 2013
The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrenceChuanbo Zhang, Bhaskar V Kallakury, Jeffrey S Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
The Journal of Infectious Diseases|October 3, 2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral TherapyDavid M Asmuth, Corbin G Thompson, Tae-Wook Chun, et al.
Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.
Transfusion|October 1, 1996
The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overviewM P Busch, A Collier, T Gernsheimer, et al.
Molecular & Cellular Proteomics : MCP|August 23, 2005
Pooled ORF expression technology (POET): using proteomics to screen pools of open reading frames for protein expressionWilliam K Gillette, Dominic Esposito, Peter H Frank, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV diseaseD H Shepp, C Ramirez-Ronda, L Dall, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
Pageof 65

Showing results (601-610 of 642) with videos related to

Sort By:
Pageof 65
Journal of Neurotrauma|December 31, 2010
Craniotomy: true sham for traumatic brain injury, or a sham of a sham?Jeffrey T Cole, Angela Yarnell, William S Kean, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
International Journal of Cancer|January 3, 2013
The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrenceChuanbo Zhang, Bhaskar V Kallakury, Jeffrey S Ross, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
ANX7, a candidate tumor suppressor gene for prostate cancerM Srivastava, L Bubendorf, V Srikantan, et al.
The Journal of Infectious Diseases|October 3, 2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral TherapyDavid M Asmuth, Corbin G Thompson, Tae-Wook Chun, et al.
Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.
Transfusion|October 1, 1996
The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overviewM P Busch, A Collier, T Gernsheimer, et al.
Molecular & Cellular Proteomics : MCP|August 23, 2005
Pooled ORF expression technology (POET): using proteomics to screen pools of open reading frames for protein expressionWilliam K Gillette, Dominic Esposito, Peter H Frank, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV diseaseD H Shepp, C Ramirez-Ronda, L Dall, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
Pageof 65